To determine if PDE4 inhibition would mitigate pulmonary fibrosis that results from targeted type II AEC injury, we treated DTR+ mice with daily doses of intraperitoneal DT for 14 days. This evidence concerns the gene PDE4A and pulmonary fibrosis.